Skip to main navigation Skip to search Skip to main content

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.

  • Jeff Porter Sharman
  • , Steven E. Coutre
  • , Richard R. Furman
  • , Bruce D. Cheson
  • , John M. Pagel
  • , Peter Hillmen
  • , Jacqueline Claudia Barrientos
  • , Andrew David Zelenetz
  • , Thomas J. Kipps
  • , Ian Flinn
  • , Paolo Ghia
  • , Michael J. Hallek
  • , Bertrand Coiffier
  • , Susan Mary OBrien
  • , Eugen Tausch
  • , Karl A Kreuzer
  • , Wendy Jiang
  • , Thomas Michael Jahn
  • , Mirella Lazarov
  • , Stephan Stilgenbauer

    Research output: Contribution to journal › Article › peer-review

    Original languageAmerican English
    JournalJournal of Clinical Oncology
    Volume32
    StatePublished - May 20 2014

    Disciplines

    • Medicine and Health Sciences
    • Pathology

    Cite this